NeoGenomics stock analysis
NeoGenomics (NG9) Stock Price & Analysis
NG9 Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 1.66B
- Enterprise Value
- CHF 2.67B
- Total Cash (Recent Filing)
- CHF 139.28M
- Total Debt (Recent Filing)
- CHF 449.14M
- Price to Earnings (P/E)
- ―
- Beta
- 1.58
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
NGS-led Growth
Rapid NGS growth supported by new products, increasing large-panel volumes and demand across multiple oncology applications indicates durable expansion potential. Its higher-value mix can lift average pricing and strengthen NeoGenomics’ position as testing increasingly shifts toward advanced genomic diagnostics.
Margin And EBITDA Improvement
Meaningful gross-margin expansion alongside strong EBITDA growth shows that revenue gains are converting more effectively into operating profit. The improvement reflects pricing, richer NGS mix and laboratory efficiencies, supporting a more scalable business model if these drivers persist.
Expanding MRD Reimbursement
Additional Medicare coverage strengthens the commercial foundation for RaDaR ST by improving access to a large patient population and reducing reimbursement uncertainty. Further indications under review could broaden adoption, reinforce the MRD franchise and expand recurring diagnostic demand over time.
Bears Say
Persistent Unprofitability
NeoGenomics has not yet translated its improving revenue, margin and operating trends into positive net earnings. Continued losses reduce retained funding for growth and leave shareholder returns negative, so execution must remain strong for operating improvements to become sustainable profitability.
Negative Free Cash Flow
Minimal operating cash generation and ongoing negative free cash flow indicate that the business is not yet consistently self-funding after investment needs. This limits financial flexibility and increases execution sensitivity if the planned margin improvement or revenue growth takes longer to materialize.
Reimbursement And Legacy Revenue Headwinds
Declining legacy pharma activity and unreimbursed MRD testing create pressure on near-term revenue quality and gross margin. Although newer businesses may offset part of the decline, the transition requires NeoGenomics to replace lower-value contracts while expanding reimbursement-supported demand.
NeoGenomics News
NG9 FAQ
What is NeoGenomics’s market cap?
When is NeoGenomics’s upcoming earnings report date?
How were NeoGenomics’s earnings last quarter?
Is NeoGenomics overvalued?
Does NeoGenomics pay dividends?
What is NeoGenomics’s EPS estimate?
How many shares outstanding does NeoGenomics have?
What happened to NeoGenomics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of NeoGenomics?
What is the TipRanks Smart Score and how is it calculated?
NeoGenomics Stock Smart Score
Company Description
NeoGenomics
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Anthony Zook
- Employees
- 2,500
- Website
- www.neogenomics.com
- Address
- 9490 NeoGenomics Way, Fort Myers, FL, 33912, US
NeoGenomics (NG9) Earnings & Revenues
NG9 Company Deck
NG9 Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, marked by 11% total revenue growth, 29% NGS growth, more than 300 basis points of adjusted gross-margin expansion, 53% adjusted EBITDA growth, and higher 2026 revenue and EBITDA guidance. Management also highlighted expanding MRD reimbursement, payer wins, product upgrades, sales-force investment, and a leadership transition occurring from a position of strength. The principal challenges were declining nonclinical revenue, legacy pharma pressure, near-term unreimbursed MRD testing, temporary receivables and cash-flow effects, and potential PAMA-related EBITDA pressure, but these issues were presented as manageable relative to the company's growth momentum.
View all CH:NG9 earnings summaries











